JP2021511359A5 - - Google Patents

Info

Publication number
JP2021511359A5
JP2021511359A5 JP2020540750A JP2020540750A JP2021511359A5 JP 2021511359 A5 JP2021511359 A5 JP 2021511359A5 JP 2020540750 A JP2020540750 A JP 2020540750A JP 2020540750 A JP2020540750 A JP 2020540750A JP 2021511359 A5 JP2021511359 A5 JP 2021511359A5
Authority
JP
Japan
Prior art keywords
alkylene
alkyl
cycloalkyl
heterocycloalkyl
optionally substituted
Prior art date
Application number
JP2020540750A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019148036A5 (https=
JP7307733B2 (ja
JP2021511359A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/015289 external-priority patent/WO2019148036A1/en
Publication of JP2021511359A publication Critical patent/JP2021511359A/ja
Publication of JP2021511359A5 publication Critical patent/JP2021511359A5/ja
Publication of JPWO2019148036A5 publication Critical patent/JPWO2019148036A5/ja
Priority to JP2023045583A priority Critical patent/JP7596427B2/ja
Application granted granted Critical
Publication of JP7307733B2 publication Critical patent/JP7307733B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020540750A 2018-01-26 2019-01-25 キナーゼ依存的障害を処置するための化合物 Active JP7307733B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023045583A JP7596427B2 (ja) 2018-01-26 2023-03-22 キナーゼ依存的障害を処置するための化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862622626P 2018-01-26 2018-01-26
US201862622629P 2018-01-26 2018-01-26
US62/622,629 2018-01-26
US62/622,626 2018-01-26
PCT/US2019/015289 WO2019148036A1 (en) 2018-01-26 2019-01-25 Compounds for the treatment of kinase-dependent disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023045583A Division JP7596427B2 (ja) 2018-01-26 2023-03-22 キナーゼ依存的障害を処置するための化合物

Publications (4)

Publication Number Publication Date
JP2021511359A JP2021511359A (ja) 2021-05-06
JP2021511359A5 true JP2021511359A5 (https=) 2022-02-24
JPWO2019148036A5 JPWO2019148036A5 (https=) 2022-02-24
JP7307733B2 JP7307733B2 (ja) 2023-07-12

Family

ID=65409542

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020540750A Active JP7307733B2 (ja) 2018-01-26 2019-01-25 キナーゼ依存的障害を処置するための化合物
JP2023045583A Active JP7596427B2 (ja) 2018-01-26 2023-03-22 キナーゼ依存的障害を処置するための化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023045583A Active JP7596427B2 (ja) 2018-01-26 2023-03-22 キナーゼ依存的障害を処置するための化合物

Country Status (19)

Country Link
US (2) US11708367B2 (https=)
EP (1) EP3743068B1 (https=)
JP (2) JP7307733B2 (https=)
KR (1) KR102759973B1 (https=)
CN (1) CN112312909B (https=)
AU (1) AU2019212719B2 (https=)
CA (1) CA3088127A1 (https=)
CL (1) CL2020001930A1 (https=)
CO (1) CO2020010467A2 (https=)
CR (2) CR20200355A (https=)
IL (2) IL276028B2 (https=)
MA (1) MA51672A (https=)
MX (2) MX2020007759A (https=)
PE (1) PE20210044A1 (https=)
PH (1) PH12020551059A1 (https=)
SA (1) SA520412488B1 (https=)
SG (1) SG11202006945PA (https=)
UA (1) UA128348C2 (https=)
WO (1) WO2019148036A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA128348C2 (uk) * 2018-01-26 2024-06-19 Екселіксіс, Інк. Сполуки для лікування кіназозалежних розладів
MA51679A (fr) 2018-01-26 2020-12-02 Exelixis Inc Composés destinés au traitement de troubles dépendant de la kinase
UA128476C2 (uk) * 2018-01-26 2024-07-24 Екселіксіс, Інк. Сполуки для лікування кіназозалежних розладів
CN112457308B (zh) 2019-09-09 2024-01-02 上海长森药业有限公司 新型三环芳香杂环化合物,及其制备方法、药物组合物和应用
WO2021180006A1 (zh) * 2020-03-10 2021-09-16 南京明德新药研发有限公司 乙烯基取代吡啶类化合物
GB202004960D0 (en) * 2020-04-03 2020-05-20 Kinsenus Ltd Inhibitor compounds
TWI887405B (zh) 2020-04-30 2025-06-21 美商艾克塞里克斯公司 製備激酶抑制劑之方法
EP4323356A1 (en) 2021-04-13 2024-02-21 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
CN117164527B (zh) * 2022-05-25 2026-02-17 大连理工大学 一种钒催化杂环芳香腈水解制备杂环芳香酰胺的方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
MX9707453A (es) 1995-03-30 1997-12-31 Pfizer Derivados de quinazolina.
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
HU228446B1 (en) 1996-04-12 2013-03-28 Warner Lambert Co Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
JP4679517B2 (ja) 2003-07-23 2011-04-27 エグゼリクシス, インコーポレイテッド 薬剤としてのアゼピン誘導体
PT2213661E (pt) * 2003-09-26 2011-12-15 Exelixis Inc Moduladores de c-met e métodos de uso
WO2006113546A2 (en) 2005-04-15 2006-10-26 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
BRPI0708615A2 (pt) 2006-03-07 2011-06-07 Array Biopharma Inc compostos de pirazol heterobicìclicos e métodos de uso
EP2340244A4 (en) * 2008-10-14 2012-07-25 Ning Xi COMPOUNDS AND APPLICATION PROCEDURES
EP2213686A1 (en) 2009-01-28 2010-08-04 Externautics S.p.A. Tumor markers and methods of use thereof
EP2214019A1 (en) 2009-01-28 2010-08-04 Externautics S.p.A. Tumor markers and methods of use thereof
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2011051277A1 (en) 2009-10-26 2011-05-05 Externautics S.P.A. Breast tumor markers and methods of use thereof
EP2493916B1 (en) 2009-10-26 2016-06-08 Externautics S.p.A. Lung tumor markers and methods of use thereof
EP2494361B2 (en) 2009-10-26 2019-01-09 Externautics S.p.A. Ovary tumor markers and methods of use thereof
WO2011051271A2 (en) 2009-10-26 2011-05-05 Externautics S.P.A. Prostate tumor markers and methods of use thereof
EP2494351B1 (en) 2009-10-26 2016-06-08 Externautics S.p.A. Colon and rectal tumor markers and methods of use thereof
EP2383578A1 (en) 2010-04-30 2011-11-02 Externautics S.p.A. Tumor marker and methods of use thereof
WO2012006960A1 (en) * 2010-07-14 2012-01-19 Zhejiang Beta Pharma Inc. NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
US8664244B2 (en) * 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
CN102093421B (zh) 2011-01-28 2014-07-02 北京康辰药业有限公司 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
CN102408411B (zh) 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
CA2886433C (en) 2012-10-04 2022-01-04 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
JP6742903B2 (ja) 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−1(pd−1)に対する抗体
US10359428B2 (en) 2013-06-14 2019-07-23 Externautics S.P.A. Tumor marker, monoclonal antibodies and methods of use thereof
KR20160093012A (ko) 2013-11-05 2016-08-05 코그네이트 바이오서비시즈, 인코포레이티드 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물
IL248408B (en) 2014-04-25 2022-06-01 Exelixis Inc A method for treating adenocarcinoma of the lungs
CN104817497B (zh) 2015-03-20 2017-03-08 南京众睿缘生物科技有限公司 一种炔代喹啉衍生物及其制备方法和用途
CN106279147A (zh) * 2015-05-21 2017-01-04 中国科学院上海药物研究所 一种吡啶并氮杂环化合物及其制备方法和用途
US20180009758A1 (en) 2015-06-29 2018-01-11 Ontogenesis, Llc Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
CN105797123A (zh) 2016-05-18 2016-07-27 王超 一种治疗不孕不育的中药组合物
CN106400155A (zh) 2016-08-31 2017-02-15 飞佛特种纺织品(宁波)有限公司 一种防老化阳光面料
CN107235896B (zh) 2016-09-13 2019-11-05 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂及其应用
SG11202005719UA (en) 2017-12-20 2020-07-29 Angex Pharmaceutical Inc Carbamate and urea compounds as multikinase inhibitors
UA128348C2 (uk) * 2018-01-26 2024-06-19 Екселіксіс, Інк. Сполуки для лікування кіназозалежних розладів

Similar Documents

Publication Publication Date Title
JP2021511359A5 (https=)
JP2021511357A5 (https=)
JP2021511360A5 (https=)
JP2023082042A5 (https=)
JPWO2019148044A5 (https=)
JP2014500265A5 (https=)
JP2021534124A5 (https=)
JP2008543886A5 (https=)
ATE450532T1 (de) Pyridinyl- oder pyrimidinylthiazole mit proteinkinasehemmender wirkung
ME01421B (me) 5-supstituisani derivati kinazolinona kao protivtumorska sredstva
RU2007116119A (ru) Производные циклоспорина, замещенные 3-эфиром и 3-тиоэфиром, для лечения и профилактики инфекционного гепатита с
JP2007516205A5 (https=)
JP2021535159A5 (https=)
JP2009536620A5 (https=)
JP2003519676A5 (https=)
RU2016125306A (ru) Новые пестицидные соединения и применения
JPWO2020117759A5 (https=)
JP2006515339A5 (https=)
CA2547347A1 (en) Diazaindole-dicarbonyl-piperazinyl antiviral agents
JP2011517697A5 (https=)
RU2015104962A (ru) Ди- и тригетероарильные производные в качестве ингибиторов агрегации белков
JP2005503435A5 (https=)
RU2004104329A (ru) Ацилсемикарбазиды как ингибиторы циклинзависимой киназы, полезные в качестве противораковых и противопролиферативных агентов
JPWO2019148036A5 (https=)
JP2009501745A5 (https=)